Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Drug Profile

Microencapsulated CYP 2B1-expressing cells - PharmaCyte Biotech

Alternative Names: Breast cancer cell therapy - PharmaCyte Biotech; CypCaps; Encapsulated cyclophosphamide-activating cells - PharmaCyte Biotech; Encapsulated ifosfamide-activating cells - PharmaCyte Biotech; NovaCaps®; Ovarian cancer cell therapy - PharmaCyte Biotech; Pancreatic cancer cell therapy - PharmaCyte Biotech

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Austrianova; SG Austria
  • Developer PharmaCyte Biotech; Translational Drug Development
  • Class Cell therapies; Chemoprotectants; Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Breast cancer; Malignant ascites; Ovarian cancer
  • Research Pain

Most Recent Events

  • 21 Mar 2017 PharmaCyte Biotech files for provisional patent protection with the United States Patent and Trademark Office for microencapsulated CYP 2B1-expressing cells
  • 01 Nov 2016 PharmaCyte Biotech requests pre-IND meeting with the US FDA
  • 15 Mar 2016 Pharmacyte Biotech has patent protection for Microencapsulated CYP 2B1-expressing cells in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top